Opzelura (ruxolitinib) is a topical Janus kinase (JAK) inhibitor. It's a non-steroid cream used to treat atopic dermatitis (eczema) and nonsegmental vitiligo (a condition where skin loses its color) in adults and children ages 12 years and older. Opzelura (ruxolitinib) is applied directly on the skin twice daily. Even though Opzelura (ruxolitinib) has the same black box warnings as oral JAK inhibitors, it's less likely to cause serious side effects compared to oral medications. Some of the more commonly reported side effects of Opzelura (ruxolitinib) include acne, itching or redness, and symptoms of the common cold.
Opzelura (ruxolitinib) is a Janus kinase (JAK) inhibitor. It works by blocking an enzyme (protein) called Janus kinase, which prevents the activation of other proteins in your immune system. This lowers inflammation (redness, swelling, pain) in the skin to treat eczema. This also prevents destruction of certain skin cells responsible for skin pigmentation (color) to treat nonsegmental vitiligo.
The following side effects may get better over time as your body gets used to the medication. Let your healthcare provider know immediately if you continue to experience these symptoms or if they worsen over time.
Atopic dermatitis:
Nonsegmental vitiligo:
Contact your healthcare provider immediately if you experience any of the following.
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):
No, Opzelura (ruxolitinib) isn't a steroid, it's a JAK inhibitor. Both steroids and JAK inhibitors lower inflammation, but they do so in different ways. Depending on what medical condition you have and how severe it is, your dermatologist might prescribe a topical corticosteroid to use with Opzelura (ruxolitinib).
No, Opzelura (ruxolitinib) isn't considered a biologic. Biologics are medications that are made from living sources, like cells. Ruxolitinib is a synthetic (lab-made) medication that's made from chemicals.
In studies looking at how well Opzelura (ruxolitinib) works for atopic dermatitis, 54% of people had clear or almost clear skin and 52% of people had much less itching after using the medication for 2 months, compared to 15% of people who experienced similar results with placebo. In studies looking at how well Opzelura (ruxolitinib) works for nonsegemental vitiligo in the face, about 30% of people had at least a 75% improvement in their skin pigmentation (color) after about 5 months of treatment, compared to .
Based on clinical studies, most people can use Opzelura (ruxolitinib) without any serious side effects if they use it as directed by their dermatologist. But some people have reported very serious side effects after using Opzelura (ruxolitinib), such as blood clots and serious respiratory infections. Based on studies, Opzelura (ruxolitinib) is less likely to cause serious side effects than oral JAK inhibitors. Talk to your dermatologist if you have concerns about using Opzelura (ruxolitinib).
No. Opzelura (ruxolitinib) is only available with a prescription from a healthcare professional.
Yes, Opzelura (ruxolitinib) can be applied on your face, as well as other sensitive parts of your body that are affected with eczema or vitiligo. But never apply Opzelura (ruxolitinib) inside your mouth, vagina, or eyes.
Talk with your dermatologist before you stop treatment. They might advise you to stop Opzelura (ruxolitinib) for eczema when your signs and symptoms (e.g., itch, rash, and redness) get better. If your signs and symptoms don't get better within 2 months of using Opzelura (ruxolitinib), your dermatologist might re-examine your condition to see if you should continue using the medication. If you're using Opzelura (ruxolitinib) for nonsegmental vitiligo and your skin hasn't gotten better after 6 months, contact your dermatologist to see if you should continue using the medication.
Opzelura (ruxolitinib) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
People who took oral JAK inhibitors have experience life-threatening infections, including fungal and viral infections. It's unclear whether topical JAK inhibitors, like Opzelura (ruxolitinib), carry that same risk. But there people who used Opzelura (ruxolitinib) have reported serious respiratory infections during treatment.
Your dermatologist will routinely monitor you for infections before and during treatment with Opzelura (ruxolitinib). If you notice any signs of infection during treatment like fever, chills, body aches, or cough, let your dermatologist know right away.
Use of oral JAK inhibitors for rheumatoid arthritis has been linked to higher risk of death for some people, such as older adults with at least one heart-related risk factor. While topical Opzelura (ruxolitinib) isn't known to have this same risk, please use this medication with caution. Talk to your dermatologist about the risks and benefits of using Opzelura (ruxolitinib) before you start treatment.
Some people who took oral JAK inhibitors reported they developed cancer during treatment. These cancers included lymphoma and skin cancer. While the same hasn't been reported with Opzelura (ruxolitinib), there's a possibility that it can also raise your risk for cancer. Because of this, your provider will monitor you for your risk of cancer during treatment. Additionally, make sure you schedule yearly screenings for skin cancer and let your dermatologist know if you notice changes to your skin. Wear protective clothing and use sunscreen if you're out in the sun, and avoid UV light (e.g., tanning beds) to lower your risk of skin cancer.
People who took oral JAK inhibitors reported blood clots in various parts of the body, including the heart and brain. While these conditions haven't been linked to Opzelura (ruxolitinib), please use it with caution. Get medical help right away if you experience symptoms of blood clots, such as:
Your dermatologist might have you stop taking Opzelura (ruxolitinib) if you experience any blood clots.
Opzelura (ruxolitinib) can cause low red blood cell (RBC), white blood cell (WBC), and platelet levels. This can raise your risk for bleeds, anemia, and infections. Your prescriber might order blood draws to check your blood cell counts, as needed. Let your prescriber know if you experience possible symptoms of low blood cell counts, such as:
Your prescriber might have you stop taking Opzelura (ruxolitinib) if you experience low blood cell counts.
Jakafi (ruxolitinib), the oral form of Opzelura (ruxolitinib), has been shown to raise cholesterol. It's not known if Opzelura (ruxolitinib) has the same risk. Let your dermatologist know if you have high cholesterol, or are taking medications for high cholesterol, before starting Opzelura (ruxolitinib). They might need to perform blood work to check your cholesterol levels.
| Dosage | Quantity | Price as low as | Price per unit |
|---|---|---|---|
| 60g of 1.5% | 1 tube | $0.00 | $0.00 |
| 100g of 1.5% | 1 tube | $0.00 | $0.00 |
Each gram of cream contains 15 mg of ruxolitinib.
Don't use more than one 60-gram tube of Opzelura (ruxolitinib) every week or one 100-gram tube every 2 weeks.